C Casulo1, B Day2, K L Dawson2, X Zhou3, C R Flowers4, C M Farber5, J D Hainsworth6, J R Cerhan7, B K Link8, A D Zelenetz9, J W Friedberg10. 1. James P. Wilmot Cancer Center, University of Rochester, Rochester. 2. Genentech, Inc., South San Francisco. 3. RTI Health Solutions, Research Triangle Park, Durham. 4. Department of Medicine, Emory University, Atlanta. 5. Carol G. Simon Cancer Center, Morristown. 6. Sarah Cannon Research Institute, Nashville. 7. Department of Health Sciences Research, Mayo Clinic, Rochester. 8. University of Iowa, Iowa City. 9. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. 10. James P. Wilmot Cancer Center, University of Rochester, Rochester jonathan_friedberg@urmc.rochester.edu.
Abstract
BACKGROUND: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, with median age at diagnosis in the seventh decade. FL in young adults (YAs), defined as diagnosis at ≤40 years, is uncommon. No standard approaches exist guiding the treatment of YA FL, and little is known about their disease characteristics and outcomes. To gain further insights into YA FL, we analyzed the National LymphoCare Study (NLCS) to describe characteristics, initial treatments, and outcomes in this population versus patients aged >40 years. PATIENTS AND METHODS: Using the NLCS database, we stratified FL patients by age: 18-40 (YA), 41-60, 61-70, 71-80, and >80 years. Survival probability was estimated using Kaplan-Meier methodology. We examined associations between age and survival using hazard ratios and 95% confidence intervals (CIs) from multivariable Cox models. RESULTS: Of 2652 eligible FL patients in the NLCS, 164 (6%) were YAs. Of YA patients, 69% had advanced disease, 80% had low-grade histology, and 50% had good-risk disease according to the Follicular Lymphoma International Prognostic Index (FLIPI). Nineteen percent underwent observation, 12% received rituximab monotherapy, and 46% received chemoimmunotherapy [in 59% of these: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)]. With a median follow-up of 8 years, overall survival (OS) at 2, 5, and 8 years was 98% (95% CI 93-99), 94% (95% CI 89-97), and 90% (95% CI 83-94), respectively. Median progression-free survival (PFS) was 7.3 years (95% CI 5.6-not reached). CONCLUSIONS: In one of the largest cohorts of YA FL patients treated in the rituximab era, disease characteristics and outcomes were similar to patients aged 41-60 years, with favorable OS and PFS in YAs. Longer-term outcomes and YA-specific survivorship concerns should be considered when defining management. These data may not support the need for more aggressive therapies in YA FL. CLINICAL TRIAL NUMBER: Roche/Genentech ML01377 (U2963n).
BACKGROUND:Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, with median age at diagnosis in the seventh decade. FL in young adults (YAs), defined as diagnosis at ≤40 years, is uncommon. No standard approaches exist guiding the treatment of YA FL, and little is known about their disease characteristics and outcomes. To gain further insights into YA FL, we analyzed the National LymphoCare Study (NLCS) to describe characteristics, initial treatments, and outcomes in this population versus patients aged >40 years. PATIENTS AND METHODS: Using the NLCS database, we stratified FL patients by age: 18-40 (YA), 41-60, 61-70, 71-80, and >80 years. Survival probability was estimated using Kaplan-Meier methodology. We examined associations between age and survival using hazard ratios and 95% confidence intervals (CIs) from multivariable Cox models. RESULTS: Of 2652 eligible FL patients in the NLCS, 164 (6%) were YAs. Of YA patients, 69% had advanced disease, 80% had low-grade histology, and 50% had good-risk disease according to the Follicular Lymphoma International Prognostic Index (FLIPI). Nineteen percent underwent observation, 12% received rituximab monotherapy, and 46% received chemoimmunotherapy [in 59% of these: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)]. With a median follow-up of 8 years, overall survival (OS) at 2, 5, and 8 years was 98% (95% CI 93-99), 94% (95% CI 89-97), and 90% (95% CI 83-94), respectively. Median progression-free survival (PFS) was 7.3 years (95% CI 5.6-not reached). CONCLUSIONS: In one of the largest cohorts of YA FL patients treated in the rituximab era, disease characteristics and outcomes were similar to patients aged 41-60 years, with favorable OS and PFS in YAs. Longer-term outcomes and YA-specific survivorship concerns should be considered when defining management. These data may not support the need for more aggressive therapies in YA FL. CLINICAL TRIAL NUMBER: Roche/Genentech ML01377 (U2963n).
Authors: Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: Shane A Gangatharan; Manjula Maganti; John G Kuruvilla; Vishal Kukreti; Rodger E Tiedemann; Mary K Gospodarowicz; David C Hodgson; Alex Sun; Richard W Tsang; Melania Pintilie; Michael Crump Journal: Br J Haematol Date: 2015-04-22 Impact factor: 6.998
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941
Authors: Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine van Glabbeke; Hanneke C Kluin-Nelemans Journal: Haematologica Date: 2006-10-17 Impact factor: 9.941
Authors: Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann Journal: Blood Date: 2014-12-01 Impact factor: 22.113
Authors: Wade T Swenson; James E Wooldridge; Charles F Lynch; Valerie L Forman-Hoffman; Elizabeth Chrischilles; Brian K Link Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113
Authors: Stefan Alig; Vindi Jurinovic; Alessandro Pastore; Deepak Bararia; Sarah Häbe; Johannes C Hellmuth; Robert Kridel; Randy Gascoyne; Christian Schmidt; Anna-Katharina Zöllner; Christian Buske; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann; Eva Hoster; Oliver Weigert Journal: Haematologica Date: 2018-03-15 Impact factor: 9.941